Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the ...

After trailing broader equities over the past few years, will the healthcare sector finally bounce back in 2026? It's hard to ...

Steel is a cyclical sector, and several catalysts could propel Nucor stock even higher through the cycle. However, there are ...

Reale talks living in New Jersey, her favorite movie, and the superpower that could make a difference on the field.

Lilly Clarke rejoins the City of Garland as the new Managing Director of Human Resources, bringing extensive municipal HR ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Antis’ Lilly Gerwert became the 16th player in program history to reach the 1,000 career point mark as she recorded a ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

With all of this in mind, let's check out my top 10 stocks to buy for 2026. They offer you a balanced blend of ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.